Eli Lilly and Company News - March 2026
🟢 LLY is trading 4% up today on news of acquiring Centessa Pharmaceuticals and expanding its AI drug discovery partnership
LLY is trading at $923.60 (+4.17%) following two significant company-specific announcements that overshadowed broader market trends. • Acquisition of Centessa...
Eli Lilly strikes $2.75B AI deal with Insilico for diabetes treatments
Eli Lilly has entered a strategic co-development partnership with Hong Kong-listed Insilico Medicine. The collaboration utilizes Insilico’s artificial...
Eli Lilly Retatrutide Hits Phase 3 Goals, Cutting Weight by Nearly 17%
Eli Lilly and Company announced positive topline results from the TRANSCEND-T2D-1 Phase 3 trial. The investigational drug retatrutide met all primary and...
Eli Lilly Drops 3.3% on Rare Sell Rating — Is Wall Street's Obesity Bet Too Big?
Shares slid as HSBC analyst Rajesh Kumar issued the only sell-equivalent rating on Eli Lilly across Wall Street, downgrading LLY to "Reduce" from "Hold" and...
Eli Lilly Commits $3B to China Supply Chain for Experimental Weight-Loss Pill
Eli Lilly and Company plans to invest $3 billion in China over the next decade. This capital will expand the company's supply chain and establish production...